Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Interest Expenses (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Interest Expenses data on record, last reported at $3.9 million in Q3 2025.

  • For Q3 2025, Interest Expenses rose 3.75% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $15.4 million, down 1.51%, while the annual FY2024 figure was $14.7 million, 10.12% up from the prior year.
  • Interest Expenses reached $3.9 million in Q3 2025 per BTAI's latest filing, down from $4.2 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $4.5 million in Q4 2023 and bottomed at $7000.0 in Q1 2022.
  • Average Interest Expenses over 4 years is $3.2 million, with a median of $3.6 million recorded in 2024.
  • The widest YoY moves for Interest Expenses: up 43242.86% in 2023, down 30.87% in 2023.
  • A 4-year view of Interest Expenses shows it stood at $3.5 million in 2022, then surged by 30.16% to $4.5 million in 2023, then fell by 20.8% to $3.6 million in 2024, then rose by 10.29% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $3.9 million in Q3 2025, $4.2 million in Q2 2025, and $3.6 million in Q1 2025.